Evidence map›Paper›PMID 40595156›Full record

ArticleScientific reports2025

Integrated plasma metabolomics and lipidomics profiling highlight distinctive signatures with hashimoto's thyroiditis.

Guoqiang Wang, Xuan Ye, Ting Lu, Yunxi Yang, Bingwei Sun, Hui Xiao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guoqiang WangDepartment of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.
Xuan YeDepartment of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.
Ting LuDepartment of Endocrinology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.
Yunxi YangResearch Center for Neutrophil Engineering Technology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.
Bingwei SunResearch Center for Neutrophil Engineering Technology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China.
Hui XiaoDepartment of Central Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215002, Jiangsu Province, China. xiaohui114618@163.com.

Funding

Science and Technology Program of Suzhou SKY2023207
6 · The paper itself

Abstract

Hashimoto's Thyroiditis (HT) is an autoimmune disorder characterized by metabolic disturbances. However, a comprehensive metabolic and lipid profile of HT has not been reported. The metabolic and lipid profile of HT can be comprehensively analyzed through metabolomics and lipidomics technologies, providing a detailed understanding of the disease's biochemical alterations. Plasma samples were obtained from 20 mice, comprising 10 from the control group and 10 from the HT group. Plasma metabolomics and lipidomics were analyzed via LC-MS/MS. PCA, PLS-DA, and OPLS-DA of the preprocessed data matrix were conducted using the ropls package (V.1.6.2) in R. The identification of significant differential metabolites was based on the VIP scores in the OPLS-DA model and p-values (Student's t-test). Metabolites (VIP exceeding 1 and p < 0.05) were classified as significantly different. Pathway annotation of these metabolites was carried out using the KEGG database to identify associated metabolic pathways. Pathway enrichment analysis was performed using the Python scipy. Stats package, with Fisher's exact test employed to identify biological pathways most relevant to the experimental conditions. Metabolomics identified 6384 metabolites (2943 in positive ion mode and 3441 in negative), with 195 differential metabolites, comprising 114 upregulated and 81 downregulated in the HT group. Lipidomics analysis revealed 1054 lipid metabolites (695 detected in positive ion mode and 359 in negative), and 247 differentially expressed lipids were identified, including 165 upregulated and 82 downregulated in the HT group. KEGG enrichment analysis indicated that metabolites upregulated in the HT group were primarily associated with pathways such as Autophagy, Choline metabolism, PPAR signaling, and Glycerophospholipid metabolism. In contrast, pathways involved in Apoptosis, Cholesterol metabolism, Sphingolipid metabolism, EGFR tyrosine kinase inhibitor resistance, Th1 and Th2 cell differentiation, viral infection, and Chemokine signaling were suppressed. Metabolic and lipidomic dysregulation was observed in HT animal models, with pronounced alterations in Phospholipids, Eicosanoids, and Carnitines. Choline, Glycerophospholipid, and Linoleic acid metabolism pathways exhibited significant enrichment in HT.

Indexed as

Hashimoto DiseaseLipidomicsLipidsMetabolomicsAnimalsChromatography, LiquidFemaleLipid MetabolismMetabolic Networks and PathwaysMetabolomeMiceTandem Mass SpectrometryLipidsCarnitinesEicosanoidsHashimoto’s thyroiditisLC-MS/MSLipidomicsMetabolomicsPhospholipids

Identifiers

PMID40595156
PMCPMC12216467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.